Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Novo Nordisk (NVO) Trailing P/Es: LLY 38, NOV 10 Forward P/Es: LLY 26, NVO 11 Estimated 2026 sales growth: LLY 26%, NVO -8% Estimated 2025 EPS growth: LLY 43%, NVO -6% Cash per share: LLY $8.14, NVO $6.07 Institutional ownership: LLY 84.6%, NVO 9.5% In terms of value, NVO has LLY beat by a mile, trading at less than a third of LLY on a trailing price-to-earnings basis and just under half of it on a forward price-to-earnings basis
Talk with your NJBC weight loss doctor to determine which formulation fits your lifestyle, medical needs, and treatment goals
This pathway does not depend on shortage-list status in the same way
Keep in mind your out-of-pocket costs may vary
Legitimacy Signals The company behind the product lists a working contact email, phone number, and support hours
5) Praluent (alirocumab) Praluent is indicated for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL cholesterol
US$ 29.87
US$ 25.92
US$ 22.95
US$ 29.21
US$ 27.22
US$ 22.19
US$ 25.68
US$ 27.98
US$ 26.57
US$ 23.84
US$ 24.56
